Azithromycin 1A Pharma 500 mg Uses

How old is patient?
sponsored

What is Azithromycin 1A Pharma 500 mg?

Azithromycin 1A Pharma 500 mg injection is used to treat bacterial infections in many different parts of the body. It is also used to prevent Mycobacterium avium complex (MAC) disease in patients infected with the human immunodeficiency virus (HIV).

Azithromycin 1A Pharma 500 mg belongs to the class of drugs known as macrolide antibiotics. It works by killing bacteria or preventing their growth. However, Azithromycin 1A Pharma 500 mg will not work for colds, flu, or other virus infections. Azithromycin 1A Pharma 500 mg injection may be used for other problems as determined by your doctor.

Azithromycin 1A Pharma 500 mg is available only with your doctor's prescription.

Once a medicine has been approved for marketing for a certain use, experience may show that it is also useful for other medical problems. Although these uses are not included in product labeling, Azithromycin 1A Pharma 500 mg is used in certain patients with the following medical condition:

Azithromycin 1A Pharma 500 mg indications

sponsored

To reduce the development of drug-resistant bacteria and maintain the effectiveness of Azithromycin 1A Pharma 500 mg Tablets and other antibacterial drugs, Azithromycin 1A Pharma 500 mg Tablets should be used only to treat infections that are proven or strongly suspected to be caused by susceptible bacteria. When culture and susceptibility information are available, they should be considered in selecting or modifying antibacterial therapy. In the absence of such data, local epidemiology and susceptibility patterns may contribute to the empiric selection of therapy.

Azithromycin 1A Pharma 500 mg Tablets are a macrolide antibacterial drug indicated for the treatment of patients with mild to moderate infections caused by susceptible strains of the designated microorganisms in the specific conditions listed below.

Mycobacterial Infections

Prophylaxis of Disseminated Mycobacterium avium complex (MAC) Disease

Azithromycin 1A Pharma 500 mg Tablets, taken alone or in combination with rifabutin at its approved dose, are indicated for the prevention of disseminated MAC disease in persons with advanced HIV infection.

Treatment of Disseminated MAC Disease

Azithromycin 1A Pharma 500 mg Tablets, taken in combination with ethambutol, are indicated for the treatment of disseminated MAC infections in persons with advanced HIV infection.

How should I use Azithromycin 1A Pharma 500 mg?

Use Azithromycin 1A Pharma 500 mg drops as directed by your doctor. Check the label on the medicine for exact dosing instructions.

Ask your health care provider any questions you may have about how to use Azithromycin 1A Pharma 500 mg drops.

Uses of Azithromycin 1A Pharma 500 mg in details

sponsored

Use: Labeled Indications

Oral, IV:

Chancroid: Treatment of genital ulcer disease (in men) due to Haemophilus ducreyi (chancroid)

Chronic obstructive pulmonary disease, acute exacerbation: Treatment of acute bacterial exacerbations of chronic obstructive pulmonary disease (COPD) due to Haemophilus influenzae, Moraxella catarrhalis, or Streptococcus pneumoniae

Mycobacterium avium complex: Prevention of Mycobacterium avium complex (MAC) in patients with advanced HIV infection; treatment of disseminated MAC (in combination with ethambutol) in patients with advanced HIV infection

Otitis media, acute: Treatment of acute otitis media due to H. influenzae, M. catarrhalis, or S. pneumoniae

Pneumonia, community-acquired: Treatment of community-acquired pneumonia (CAP) due to Chlamydophila pneumoniae, H. influenzae, Legionella pneumophila, M. catarrhalis, Mycoplasma pneumoniae, or S. pneumoniae

Skin and skin structure infection, uncomplicated: Treatment of uncomplicated skin and skin structure infections due to Staphylococcus aureus, Streptococcus pyogenes, or Streptococcus agalactiae

Streptococcal pharyngitis (group A): Treatment of pharyngitis/tonsillitis due to S. pyogenes as an alternative to first-line therapy

Urethritis/cervicitis: Treatment of urethritis and cervicitis due to Chlamydia trachomatis or Neisseria gonorrhoeae

Off Label Uses

Acne vulgaris

Data from controlled trials support the use of Azithromycin 1A Pharma 500 mg in the treatment of acne vulgaris in adults with moderate to severe acne.

Based on the American Academy of Dermatology guidelines of care for the management of acne vulgaris, Azithromycin 1A Pharma 500 mg, in combination with topical therapy, may be considered as a treatment option for moderate and severe acne and forms of inflammatory acne that are resistant to topical treatments. However, its use should be limited to patients who cannot receive a tetracycline (ie, pregnant women). Concomitant topical therapy with benzoyl peroxide or a retinoid should be administered with systemic antibiotic therapy (eg, Azithromycin 1A Pharma 500 mg) and continued for maintenance after the antibiotic course is completed.

Babesiosis

Data from a prospective, nonblinded, randomized trial in patients with non-life-threatening babesiosis, support the use of Azithromycin 1A Pharma 500 mg (in combination with atovaquone) for the treatment of this condition.

Based on the CDC Yellow Book, the ACG guideline for the diagnosis, treatment, and prevention of acute diarrheal infections in adults, and the IDSA practice guidelines for the diagnosis and management of infectious diarrhea, Azithromycin 1A Pharma 500 mg is effective and recommended treatment for patients with travelers' diarrhea. Due to increased levels of resistance to fluoroquinolones, Azithromycin 1A Pharma 500 mg may be a recommended first-line treatment, especially in regions with a high prevalence of Campylobacter (eg, Southeast Asia, India) or in geographical areas with suspected fluoroquinolone-resistant pathogens or enterotoxigenic Escherichia coli.

Azithromycin 1A Pharma 500 mg description

sponsored

Each film-coated tablet contains Azithromycin dihydrate equivalent to Azithromycin 1A Pharma 500 mg 500 mg.

Azithromycin 1A Pharma 500 mg is a nitrogen-containing macrolide or azalide with actions and uses similar to those of erythromycin. Azithromycin 1A Pharma 500 mg is derived from erythromycin. However, it differs chemically from erythromycin in that a methyl-substituted nitrogen atom is incorporated into the lactone ring.

Azithromycin 1A Pharma 500 mg dosage

Not for pediatric use.

For pediatric patients, please refer to the INDICATIONS AND USAGE and DOSAGE AND ADMINISTRATION sections of the prescribing information for Azithromycin 1A Pharma 500 mg for oral suspension 100 mg/5 mL and 200 mg/5 mL bottles.

Azithromycin 1A Pharma 500 mg Tablets may be taken without regard to food. However, increased tolerability has been observed when tablets are taken with food.

Mycobacterial Infections

Prevention of Disseminated MAC Infections

The recommended dose of Azithromycin 1A Pharma 500 mg Tablets for the prevention of disseminated Mycobacterium avium complex (MAC) disease is: 1200 mg taken once weekly. This dose of Azithromycin 1A Pharma 500 mg Tablets may be combined with the approved dosage regimen of rifabutin.

Treatment of Disseminated MAC Infections

Azithromycin 1A Pharma 500 mg Tablets should be taken at a daily dose of 600 mg, in combination with ethambutol at the recommended daily dose of 15 mg/kg. Other antimycobacterial drugs that have shown in vitro activity against MAC may be added to the regimen of Azithromycin 1A Pharma 500 mg plus ethambutol at the discretion of the physician or health care provider.

Azithromycin 1A Pharma 500 mg interactions

See also:
What other drugs will affect Azithromycin 1A Pharma 500 mg?

sponsored

Antacids: In a pharmacokinetic study investigating the effects of simultaneous administration of antacid with Azithromycin 1A Pharma 500 mg, no effects on overall bioavailability was seen although peak serum concentrations were reduced by up to 30%. In patients receiving both Azithromycin 1A Pharma 500 mg and antacids, the drug should not be taken simultaneously.

Carbamazepine: In a pharmacokinetic interaction study in healthy volunteers, no significant effect was observed on the plasma levels of carbamazepine or its active metabolite in patients receiving concomitant Azithromycin 1A Pharma 500 mg.

Cimetidine: A single dose of cimetidine administered 2 hrs before Azithromycin 1A Pharma 500 mg had no effect on the pharmacokinetics of Azithromycin 1A Pharma 500 mg.

Cyclosporin: In the absence of conclusive data from pharmacokinetics or clinical studies investigating potential interaction between Azithromycin 1A Pharma 500 mg and cyclosporin, caution should be exercised before concurrent administration of these drugs. If co-administration of these drugs is necessary, cyclosporin levels should be monitored and the dose adjusted accordingly.

Digoxin: Some of the macrolide antibiotics have been reported to impair the metabolism of digoxin (in the gut) in some patients. Therefore, in patients receiving concomitant Azithromycin 1A Pharma 500 mg and digoxin, the possibility of raised digoxin levels should be bourne in mind, and digoxin levels monitored.

Ergot Derivatives: Because of the theoretical possibility of ergotism, Azithromycin 1A Pharma 500 mg and ergot derivatives should not be co-administered.

Methylprednisolone: In a pharmacokinetic interaction study in healthy volunteers, Azithromycin 1A Pharma 500 mg had no significant effect on the pharmacokinetics of methylprednisolone.

Terfenadine: Pharmacokinetic studies have reported no evidence of an interaction between Azithromycin 1A Pharma 500 mg and terfenadine. There have been rare cases reported where the possibility of such an interaction could not be entirely excluded; however, there was no specific evidence that such an interaction had occured.

Theophylline: There is no evidence of any pharmacokinetic interaction when Azithromycin 1A Pharma 500 mg and theophylline are co-administered in healthy volunteers.

Coumarin-Type

Oral Anticoagulants:

In a pharmacodynamic interaction study, Azithromycin 1A Pharma 500 mg did not alter the anticoagulant effect of a single dose warfarin 15 mg administered to healthy volunteers. There have been reports received in the post-marketing period of potentiated anticoagulant subsequent to co-administration of Azithromycin 1A Pharma 500 mg and coumarin-type oral anticoagulants. Although a causal relationship has not been established, consideration should be given to the frequency of monitoring prothrombin time when Azithromycin 1A Pharma 500 mg is used in patients receiving coumarin-type oral anticoagulants.

Zidovudine: Single 1000 mg doses, and multiple 1200 mg or 600 mg doses of Azithromycin 1A Pharma 500 mg did not affect the plasma pharmacokinetics or urinary excretion of zidovudine or its glucuronide metabolite. However, administration of Azithromycin 1A Pharma 500 mg increased the concentrations of phosphorylated zidovudine, the clinically active metabolite, in peripheral blood mononuclear cells. The clinical significance of this finding is unclear, but it may be of benefit to patients.

Didanosine: Co-administration of daily doses of Azithromycin 1A Pharma 500 mg 1200 mg with didanosine in 6 subjects did not appear to affect the pharmacokinetics of didanosine as compared with placebo.

Rifabutin: Co-administration of Azithromycin 1A Pharma 500 mg and rifabutin did not affect the serum concentrations of either drug. Neutropenia was observed in subjects receiving concomitant treatment of Azithromycin 1A Pharma 500 mg and rifabutin. Although neutropenia has been associated with the use of rifabutin, a causal relationship to combination with Azithromycin 1A Pharma 500 mg has not been established.

Azithromycin 1A Pharma 500 mg side effects

See also:
What are the possible side effects of Azithromycin 1A Pharma 500 mg?

Applies to Azithromycin 1A Pharma 500 mg ophthalmic: ophthalmic solution

In addition to its needed effects, some unwanted effects may be caused by Azithromycin 1A Pharma 500 mg ophthalmic. In the event that any of these side effects do occur, they may require medical attention.

Major Side Effects

You should check with your doctor immediately if any of these side effects occur when taking Azithromycin 1A Pharma 500 mg ophthalmic:

Less common:

Rare

Minor Side Effects

Some of the side effects that can occur with Azithromycin 1A Pharma 500 mg ophthalmic may not need medical attention. As your body adjusts to the medicine during treatment these side effects may go away. Your health care professional may also be able to tell you about ways to reduce or prevent some of these side effects. If any of the following side effects continue, are bothersome or if you have any questions about them, check with your health care professional:

Rare

Azithromycin 1A Pharma 500 mg contraindications

See also:
What is the most important information I should know about Azithromycin 1A Pharma 500 mg?

Hypersensitivity

Azithromycin 1A Pharma 500 mg Tablets are contraindicated in patients with known hypersensitivity to Azithromycin 1A Pharma 500 mg, erythromycin, any macrolide, or ketolide drug.

Hepatic Dysfunction

Azithromycin 1A Pharma 500 mg Tablets are contraindicated in patients with a history of cholestatic jaundice/hepatic dysfunction associated with prior use of Azithromycin 1A Pharma 500 mg.

Active ingredient matches for Azithromycin 1A Pharma 500 mg:

Azithromycin in Austria, Hungary.


List of Azithromycin 1A Pharma 500 mg substitutes (brand and generic names)

Sort by popularity
Unit description / dosage (Manufacturer)Price, USD
Tablet, Film-Coated; Oral; Azithromycin Monohydrate 250 mg
Tablets, Film-Coated; Oral; Azithromycin Monohydrate 250 mg
AZITHROTON tab 250 mg x 6's (Walton)
AZITHROTON tab 500 mg x 3's (Walton)$ 0.75

References

  1. DailyMed. "AZITHROMYCIN: DailyMed provides trustworthy information about marketed drugs in the United States. DailyMed is the official provider of FDA label information (package inserts).". https://dailymed.nlm.nih.gov/dailyme... (accessed September 17, 2018).
  2. PubChem. "azithromycin". https://pubchem.ncbi.nlm.nih.gov/com... (accessed September 17, 2018).
  3. DrugBank. "azithromycin". http://www.drugbank.ca/drugs/DB00207 (accessed September 17, 2018).

Reviews

The results of a survey conducted on ndrugs.com for Azithromycin 1A Pharma 500 mg are given in detail below. The results of the survey conducted are based on the impressions and views of the website users and consumers taking Azithromycin 1A Pharma 500 mg. We implore you to kindly base your medical condition or therapeutic choices on the result or test conducted by a physician or licensed medical practitioners.

User reports

Consumer reported useful

No survey data has been collected yet


Consumer reported price estimates

No survey data has been collected yet


1 consumer reported time for results

To what extent do I have to use Azithromycin 1A Pharma 500 mg before I begin to see changes in my health conditions?
As part of the reports released by ndrugs.com website users, it takes 2 days and a few days before you notice an improvement in your health conditions.
Please note, it doesn't mean you will start to notice such health improvement in the same time frame as other users. There are many factors to consider, and we implore you to visit your doctor to know how long before you can see improvements in your health while taking Azithromycin 1A Pharma 500 mg. To get the time effectiveness of using Azithromycin 1A Pharma 500 mg drug by other patients, please click here.
Users%
2 days1
100.0%


Consumer reported age

No survey data has been collected yet


Consumer reviews


There are no reviews yet. Be the first to write one!


Your name: 
Email: 
Spam protection:  < Type 25 here

Information checked by Dr. Sachin Kumar, MD Pharmacology

| Privacy Policy
This site does not supply any medicines. It contains prices for information purposes only.
© 2003 - 2024 ndrugs.com All Rights Reserved